Mallinckrodt's SpecGx Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation Of Roxicodone; In Letter, FDA Provided Guidance Regarding Areas Needing Further Evaluation For Resubmission